Literature DB >> 6208924

Inhibition of the recovery from potentially lethal damage by lonidamine.

G M Hahn, I van Kersen, B Silvestrini.   

Abstract

Lonidamine [1-(2,4-dichlorobenzyl)-1-H-indazol-3-carboxylic acid] is shown to inhibit recovery from potentially lethal damage after exposure of cells to X-rays, methyl methane sulfonate, or bleomycin and heat (43 degrees C, 1h). Inhibition is most effective when the drug is present before and after exposure of 10 to 25 mg l-1, a concentration readily achievable in vivo.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6208924      PMCID： PMC1976972          DOI： 10.1038/bjc.1984.232

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  11 in total

1.  Response of human osteosarcoma in vitro to irradiation: evidence for unusual cellular repair activity.

Authors:  R Weichselbaum; J B Little; J Nove
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1977-03

2.  Influence of misonidazole on the radiosensitivity of a human melanoma in nude mice: time-dependent increase in surviving fraction.

Authors:  M Guichard; F de Langen-Omri; E P Malaise
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-04       Impact factor: 7.038

3.  Repair of potentially lethal damage in x-irradiated HeLa cells.

Authors:  R A Phillips; L J Tolmach
Journal:  Radiat Res       Date:  1966-11       Impact factor: 2.841

4.  Potentially lethal damage versus sublethal damage: independent repair processes in actively growing Chinese hamster cells.

Authors:  H Utsumi; M M Elkind
Journal:  Radiat Res       Date:  1979-02       Impact factor: 2.841

5.  Modification of recovery from potentially lethal x-ray damage in plateau phase Chinese hamster cells.

Authors:  R G Evans; M A Bagshaw; L F Gordon; S D Kurkjian; G M Hahn
Journal:  Radiat Res       Date:  1974-09       Impact factor: 2.841

6.  Effects of beta-arabinofuranosyladenine on the growth and repair of potentially lethal damage in Ehrilch ascites tumor cells.

Authors:  G Iliakis
Journal:  Radiat Res       Date:  1980-09       Impact factor: 2.841

7.  Plateau-phase cultures of mammalian cells: an in vitro model for human cancer.

Authors:  G M Hahn; J B Little
Journal:  Curr Top Radiat Res Q       Date:  1972-07

8.  Enhanced cell killing by bleomycin and 43 degrees hyperthermia and the inhibition of recovery from potentially lethal damage.

Authors:  J Braun; G M Hahn
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

9.  Recovery of cells from induced, potentially lethal damage.

Authors:  G M Hahn
Journal:  Cancer Treat Rep       Date:  1976-12

10.  Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo.

Authors:  P R Twentyman; N M Bleehen
Journal:  Br J Cancer       Date:  1975-10       Impact factor: 7.640
View more
  13 in total

1.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  The combined use of radiation therapy and lonidamine in the treatment of brain metastases.

Authors:  L M DeAngelis; V E Currie; J H Kim; G Krol; M A O'Hehir; F M Farag; C W Young; J B Posner
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

3.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Authors:  K W Rosbe; T W Brann; S A Holden; B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Authors:  O Ben-Yoseph; J C Lyons; C W Song; B D Ross
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

6.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

7.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.

Authors:  S Savini; W Zoli; O Nanni; A Volpi; G L Frassineti; E Magni; A Flamigni; A Amadori; D Amadori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

9.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

10.  Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.

Authors:  M De Cesare; G Pratesi; A Giusti; D Polizzi; F Zunino
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.